viDA Therapeutics
banner2.png
 
 

viDA is creating novel drugs for the treatment of inflammatory and autoimmune diseases based on our cutting-edge work in the field of granzymes.

 
 
 

viDA is dedicated to advancing novel therapeutics that target a group of serine proteases known as granzymes. Human granzyme consist of five variants (Gzm A, B, H, K and M). Originally perceived solely as immune cell-secreted enzymes responsible for cell elimination, we now understand that these protein-cleaving agents are pivotal in disrupting epithelial barriers, inducing vascular leakage, degrading the extracellular matrix, and promoting inflammation. These actions significantly contribute to various inflammatory and autoimmune diseases. Through our innovative approach, utilizing proprietary first-in-class inhibitors of granzymes, we have demonstrated positive therapeutics outcomes in relevant disease models.

viDA brings together an experienced teams of leaders, innovators, and entrepreneurs to develop a new generation of therapeutics for inflammation and autoimmune diseases. Based on the seminal work of our scientific founder, Dr. David Granville, we are introducing the first proprietary inhibitors of this family of proteases, known as​ granzymes.

Working with a team of investors and collaborators, viDA is amassing the resources to develop and deliver new therapeutic solutions for patients with inflammatory and autoimmune diseases including immune-mediated skin diseases (autoimmune blister diseases, dermatitis, itch), ophthalmology (retinal and corneal), and other chronic immune related disorders including musculoskeletal and respiratory (airway epithelium) indications.

 

Immunodermatology

Leveraging our innovative research on the role of granzymes in chronic inflammatory skin ailments, viDA is developing first-in-class, high value drugs to treat these diseases.

Ophthalmology

Our research has shown that granzymes play a significant pathological role in chronic ocular conditions, and we are developing novel therapeutics to address these diseases.

Chronic Immune-Related Diseases

By defining granzyme mechanisms in chronic immune related disorders, viDA is paving the way for granzyme inhibition to be a high value therapeutic strategy.

 

Management

 
 

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

BUSINESS DEVELOPMENT

At viDA, we are actively seeking to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.